The primary objectives of the Administrative Core of the Johns Hopkins Rheumatic DiseasesResource-based Core Center (RDRCC) are to integrate all scientific and enrichment activities ofthe Cores, maintain communication between the Cores and with the research base, and providebudgetary management and oversight, all within the context of the overall Divisional andinstitutional clinical/ translational research framework. The RDRCC and its Administrative Coreis led by Drs. Antony Rosen and Clifton Bingham (as Co-Directors). Their complementaryresearch approaches from the opposite ends of the research spectrum (laboratory and clinicalrespectively) underscore the Center's ability to enable research along the entire translationalresearch continuum.
The Specific Aims of the Administrative Core of the RDRCC are to:1)Oversee, coordinate, and actively manage the logistic and financial aspects of three ScientificCores (Core B--Research Management and Patient Integrated Data [RAPID], Core C--SampleProcessing and Immunoassay Research, SPIRE; and Core D--Data Science); 2) Continuallywork to decrease barriers to effective, cross-disciplinary interaction amongst investigatorsfocused on the rheumatic diseases; 3) Use innovative approaches to interface with theDivisional Discovery Fund program and institutional resources to maximize RDRCC Coreutilization by novel projects focused on the rheumatic diseases; 4) Foster the careers of juniorinvestigators; 5) Initiate and support innovative collaborations between Center investigators andinvestigators new to rheumatic diseases with complementary expertise and interests; 6)Coordinate a program of enrichment activities to enhance research methodological literacy andthe overall intellectual environment across disciplines. Each of these components will worktogether through the Administrative Core to enable research in the Rheumatic Diseases tothrive and expand.
|Leung, Ying Ying; Ogdie, Alexis; Orbai, Ana-Maria et al. (2018) Classification and Outcome Measures for Psoriatic Arthritis. Front Med (Lausanne) 5:246|
|Bartlett, S J; Gutierrez, A K; Butanis, A et al. (2018) Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Qual Life Res 27:2443-2451|
|Darrah, Erika; Yu, Fang; Cappelli, Laura C et al. (2018) Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol :|
|Albayda, Jemima; Bingham 3rd, Clifton O; Shah, Ami A et al. (2018) Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford) 57:760-762|
|Cappelli, Laura C; Konig, Maximilian F; Gelber, Allan C et al. (2018) Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. Arthritis Res Ther 20:59|
|Igusa, Takeru; Hummers, Laura K; Visvanathan, Kala et al. (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77:1179-1186|
|Cappelli, Laura C; Brahmer, Julie R; Forde, Patrick M et al. (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553-557|
|Lee, Yvonne C; Bingham 3rd, Clifton O; Edwards, Robert R et al. (2018) Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Arthritis Care Res (Hoboken) 70:197-204|
|Moseley, Kendall F; Naidoo, Jarushka; Bingham, Clifton O et al. (2018) Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer 6:104|
|Albayda, Jemima; Khan, Aamna; Casciola-Rosen, Livia et al. (2018) Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47:552-556|
Showing the most recent 10 out of 22 publications